We conducted a retrospective review analyzing outcomes of maintenance therapy with bortezomib after autologous stem cell transplantation A total of 102 patients treated from 2005 to 2015 were analyzed Two percent of patients required discontinuation of bortezomib maintenance because of adverse events Bortezomib in the maintenance setting is well tolerated and efficacious, and it can be continued without evidence of secondary malignancy until disease progression